Brief: OxiGENE gets FDA nod for ovarian cancer drug study design
01/06/2015 13:30
June 1 (Reuters) - OXiGENE Inc OXGN.O : * Receives guidance from FDA supporting phase 3 trial of fosbretabulin/bevacizumab combination in platinum-resistant ovarian cancer * FDA agreed with co's proposal to test combination anti-vascular regimen of fosbretabulin and bevacizumab directly against chemotherapy * FDA requested inclusion of a third arm in the trial to further characterize the efficacy of each individual drug in the combination * Says Oxigene intends to submit an application to the FDA for a special protocol assessment (spa) later this year * Source text for Eikon ID:nGNXVDSBFa * Further company coverage OXGN.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas